Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05994053 · ClinicalTrials.gov registry record · NA

Neuromodulation for a Novel OCD Biomarker and Treatment

A NA study of OCD, sponsored by Boston University Charles River Campus.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT05994053 is a NA study of OCD that is actively recruiting participants, run by Boston University Charles River Campus. The registered enrollment target is 90 participants, below the 813-participant average among 18 other OCD trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05994053, a NA study of OCD, is actively recruiting participants, sponsored by Boston University Charles River Campus.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study by Dr. Reinhart and his team will test a new, non-invasive, and well-tolerated neuromodulation method for reducing OCD symptoms, based on reward-related rhythms of the orbitofrontal cortex (OFC; a brain region responsible for reward, decision making and other crucial functions that is affected by OCD). This proposal is based on highly encouraging preliminary data in both subsyndromal and treatment-resistant populations that shows rapid reductions in OCD behaviors that last at least 1-3 months. Using high-definition transcranial alternating current stimulation (HD-tACS) guided by EEG brain wave recordings, the study will test whether repetitive modulation of relevant rhythm activity in the OFC can lead to rapid (within five days) and sustainable (up to three months) OCD symptom reduction. This research aims to increase knowledge of OCD and development of effective treatment with minimal side effects.

Conditions Studied

Interventions

  • DEVICE high definition transcranial alternating current stimulation

Study Locations (1)

Massachusetts

  • Boston University Center for Anxiety and Related Disorders (BU-CARD) - Boston

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-07-01
Est. Completion 2026-08-31
Phase NA

What the Registry Record Tells You About NCT05994053

The ClinicalTrials.gov registry entry for NCT05994053 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 813-participant average among 18 other OCD trials with a reported enrollment target (89% lower). The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with OCD appearing as the primary indexed condition, and to 1 intervention - of which high definition transcranial alternating current stimulation is the first listed.

NCT05994053 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05994053 about?

NCT05994053 is a clinical study titled "Neuromodulation for a Novel OCD Biomarker and Treatment". Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study b...

What is the current status of trial NCT05994053?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2024-07-01. Estimated completion is 2026-08-31.

What conditions does trial NCT05994053 study?

This clinical trial studies the following conditions: OCD.

What interventions are being tested in trial NCT05994053?

The interventions under investigation include: high definition transcranial alternating current stimulation (DEVICE).

Who is sponsoring clinical trial NCT05994053?

This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05994053 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for OCD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.